Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

Sponsor
University Hospital Tuebingen
Study ID
NCT06487832
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Subcutaneous GLP1-RA — OTHER
    Subcutaneous administration of semaglutide
  • Subcutaneous placebo — OTHER
    Subcutaneous administration of NaCl

Study Details

The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.

Key Dates

First listed
Jul 5, 2024
Start date
Jul 1, 2024
Status verified
Jun 2024
Primary completion
Jul 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: GLP-1
    Acute administration of 0.25 mg semaglutide (0.19 ml)
  • Placebo Comparator: Placebo
    Acute administration of 0.19 ml NaCl

Primary Outcome Measure

Cerebral response after insulin compared to placebo nasal spray [ Time Frame: 24 hours after semaglutide or placebo administration ]

Central Contacts

Find similar trials

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies